Cargando…
When Standard Therapy Fails in Breast Cancer: Current and Future Options for HER2-Positive Disease
The area of HER2-positive breast cancer is a rapidly changing field. The use of the humanized monoclonal antibody, trastuzumab, significantly improved the prognosis for patients with HER2-positive breast cancer, however, increasing knowledge regarding mechanisms of resistance to trastuzumab have com...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3920550/ https://www.ncbi.nlm.nih.gov/pubmed/24527366 http://dx.doi.org/10.4172/2167-0870.1000129 |